Healthcare Industry News: IGRT
News Release - May 9, 2006
Worldwide Acceptance of the CyberKnife(R) System Continues to GrowNew CyberKnife System Installations Make Radiosurgery an Option for More Cancer Patients Worldwide
SUNNYVALE, Calif., May 9 (HSMN NewsFeed) -- Accuray Incorporated, the global leader in the field of robotic radiosurgery, announced today that Greece and Vietnam installed their first CyberKnife® Robotic Radiosurgery Systems, making intelligent robotic radiosurgery an option for more cancer patients worldwide. The new installations indicate growing global acceptance of the CyberKnife System as an essential tool in the treatment of tumors anywhere in the body. To date, hospitals in 11 countries outside the U.S. including Germany, Italy, Japan, Korea, Malaysia, Netherlands, Singapore, Taiwan, and Turkey have installed the CyberKnife System.
Last year, the Anadolu Medical Center in Turkey installed the first CyberKnife System in Eurasia. "The addition of the CyberKnife System to Anadolu Medical Center means that for the first time ever, patients in Turkey and the surrounding region can access one of the most advanced cancer treatments available," said Dr. Kayihan Engin, director of radiation oncology, Anadolu Medical Center. "In Turkey where lung cancer is the most common form of cancer, the CyberKnife System will play a critical role for treating patients with inoperable and complex tumors."
The CyberKnife System is designed to treat tumors anywhere in the body with sub-millimeter accuracy. It is equipped with the Synchrony(TM) Respiratory Tracking System, a unique tool designed to treat tumors in the lung and other parts of the anatomy that move with respiration. Synchrony allows patients to breathe normally throughout their treatment without breath-holding or radiation beam gating techniques, so the system can track, detect and correct for tumor and patient movement throughout the treatment minimizing damage to surrounding healthy tissue.
According to the World Health Organization, cancer cases around the world are rising with 30 million total cases expected over the next 20 years. The increase in the incidence of cancer is led by lung cancer, which is now the most frequently diagnosed cancer in the world. With the global incidence of lung cancer on the rise, the disease is expected to remain a major cause of worldwide cancer death in the 21st century.(i)
"Given the devastating effects of cancer worldwide and its predicted growth in the coming years, now more than ever it is crucial that patients have access to the advanced tumor treatment provided by the CyberKnife System," said Euan Thomson, president and chief executive officer of Accuray. "We are confident that as acceptance of the CyberKnife System grows, it will bring additional treatment options to more cancer patients throughout the world."
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife System is the world's first and only radiosurgery system that utilizes intelligent robotics to treat tumors anywhere in the body with sub-millimeter accuracy. The CyberKnife System treats patients in single or staged (typically 2-5) sessions by delivering multiple beams of precisely directed radiation that converge upon the tumor while minimizing injury to surrounding healthy tissue. Image guidance and computer controlled robotics combine to continuously track, detect and correct for tumor and patient movement throughout the treatment. Because of its precision and accuracy, no head or body frame is required. The CyberKnife has proven to attract a new patient population to a physician's practice and complements existing radiation therapy, IMRT or IGRT programs.
Accuray Inc., a privately held company based in Sunnyvale, Calif., is the global leader in the field of robotic radiosurgery. Its CyberKnife System is the world's first and only intelligent robotic radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. More than 100 CyberKnife Systems have been acquired by leading medical centers throughout the world. To date, more than 20,000 patients worldwide have been treated with the CyberKnife System. For more information, please visit www.accuray.com.
For media inquiries, please contact Jeff Speer at email@example.com or 310-577-7870, ext. 156.
© 2006 Accuray Incorporated. All rights reserved. Accuray, the Accuray logo, CyberKnife, Synchrony, Xsight and CyRIS are among trademarks or registered trademarks of Accuray Incorporated.
(i) Gezairy, Hussein A., M.D. ''WHO Eastern Mediterranean Region.''
Regional Consultation on Lung Cancer Prevention and Care. June 2004.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSwiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer